Photo taken from Agenus/LinkedIn
May 17, 2024, 11:18
Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA
Agenus shared on LinkedIn:
“Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer.
Learn more.”
Source: Agenus/LinkedIn